We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Adaptimmune Awarded £2.1m from the Biomedical Catalyst Fund

News   Mar 25, 2014

 
Adaptimmune Awarded £2.1m from the Biomedical Catalyst Fund
 
 
Advertisement
 

RELATED ARTICLES

Complex Role of Immune Molecule in Huntington’s Disease

News

Abnormally high levels of an immune-system molecule, interleukin-6 (IL-6), prior to Huntington’s disease symptoms suggested it led to disease progression. However, Huntington’s model mice bred to lack IL-6 showed exacerbated symptoms compared to mice that still had it, indicating a complex relationship.

READ MORE

How A Protein Can Inhibit Cancer Development in Mice

News

Researchers have discovered how the protein PP2A can inhibit tumor growth in mice.

READ MORE

Trial Investigates Remdesivir–Baricitinib Combo as COVID-19 Treatment

News

Following on from remdesivir’s promising results from previous studies, a new trial is now investigating remdesivir in combination with baricitinib or placebo as a treatment for COVID-19, in a double-blind, randomized trial.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE